Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications – a single center experience from India.

A matched sibling donor is available for only 30-40% of patients needing a curative stem cell transplant [SCT] and for Indian patients, the chances of finding a 10/10 HLA identical unrelated donor within small donor registries is about 14% while it potentially could increase to 60% with registries that have more than 1,000,000 registered donors1. Therefore, an increasing number of haplo-identical transplants are being performed in India using the post-transplant cyclophosphamide [PTCY] platform developed by the John Hopkins group2,3.

Source: Biology of Blood and Marrow Transplantation - October 1, 2021 Category: Hematology Authors: Biju George, Uday Kulkarni, Sharon Lionel, Anup J Devasia, Fouzia N Aboobacker, Kavitha M Lakshmi, Sushil Selvarajan, Anu Korula, Winsley Rose, George M Varghese, Priscilla Rupali, Balaji V, Joy Sarojini Michael, Asha Abraham, Aby Abraham, Vikram Mathews Source Type: research